Evidence map›Paper›PMID 25388133›Full record

ReviewCurrent topics in microbiology and immunology2015

Leptospirosis in humans.

David A Haake, Paul N Levett

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Current topics in microbiology and immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 582 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
582citing papers in PubMed, 7 pooled it
50.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03912506 completednot on this mapstarted 2017, after this paper: background citation

Severe Leptospirosis in Non-tropical Areas: a Nationwide, Multicentre, Retrospective Study in French ICUs

TypeobservationalSponsorNantes University HospitalRan2017 to 2018Enrolled160ConditionsLeptospirosis, Intensive Care Unit, Epidemiology, Alveolar Hemorrhage
NCT07127718 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Decreasing Leptospirosis Emergence Through Prognosis and Treatment Optimization (DeLEPTO) Project 1: Preventive Strategies for Early and Late Complications of Leptospirosis

TypeinterventionalSponsorNational Kidney and Transplant Institute, PhilippinesRan2024 to 2027Enrolled678ConditionsLeptospirosisArmsProphylactic Plasma Transfusion, Hemoperfusion, Extracorporeal Membrane Oxygenation, Conventional therapy
3 · Its place in the literature

Who cites it

582 citing papers in PubMed, 7 syntheses or guidelines pooled it, 943 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Corticosteroids for treatment of leptospirosis.The Cochrane database of systematic reviews · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Antibiotic prophylaxis for leptospirosis.The Cochrane database of systematic reviews · 2024
    Pooled it
  7. Antibiotics for treatment of leptospirosis.The Cochrane database of systematic reviews · 2024
    Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Application of FT-IR spectroscopy using the IR BiotyperEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article

522 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

David A HaakeDivision of Infectious Diseases, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA, dhaake@ucla.edu.
Paul N Levett
Saskatchewan Disease Control Laboratory · CAVA Greater Los Angeles Healthcare System · US

Funding

Outer Membrane Proteins of Pathogenic Leptospira SpeciesR01AI034431 · NIAID · BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE · PI GOMES-SOLECKI, MARIA, HAAKE, DAVID A · 2003 to 2015
$4.1M
The Leptospiral Outer Membrane Proteome & ImmunityI01BX002003 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI MATSUNAGA, JAMES · 2014 to 2022
–
BLRD VA I01 BX002003NIAID NIH HHS R01 AI034431
6 · The paper itself

Abstract

Leptospirosis is a widespread and potentially fatal zoonosis that is endemic in many tropical regions and causes large epidemics after heavy rainfall and flooding. Infection results from direct or indirect exposure to infected reservoir host animals that carry the pathogen in their renal tubules and shed pathogenic leptospires in their urine. Although many wild and domestic animals can serve as reservoir hosts, the brown rat (Rattus norvegicus) is the most important source of human infections. Individuals living in urban slum environments characterized by inadequate sanitation and poor housing are at high risk of rat exposure and leptospirosis. The global burden of leptospirosis is expected to rise with demographic shifts that favor increases in the number of urban poor in tropical regions subject to worsening storms and urban flooding due to climate change. Data emerging from prospective surveillance studies suggest that most human leptospiral infections in endemic areas are mild or asymptomatic. Development of more severe outcomes likely depends on three factors: epidemiological conditions, host susceptibility, and pathogen virulence (Fig. 1). Mortality increases with age, particularly in patients older than 60 years of age. High levels of bacteremia are associated with poor clinical outcomes and, based on animal model and in vitro studies, are related in part to poor recognition of leptospiral LPS by human TLR4. Patients with severe leptospirosis experience a cytokine storm characterized by high levels of IL-6, TNF-alpha, and IL-10. Patients with the HLA DQ6 allele are at higher risk of disease, suggesting a role for lymphocyte stimulation by a leptospiral superantigen. Leptospirosis typically presents as a nonspecific, acute febrile illness characterized by fever, myalgia, and headache and may be confused with other entities such as influenza and dengue fever. Newer diagnostic methods facilitate early diagnosis and antibiotic treatment. Patients progressing to multisystem organ failure have widespread hematogenous dissemination of pathogens. Nonoliguric (high output) renal dysfunction should be supported with fluids and electrolytes. When oliguric renal failure occurs, prompt initiation of dialysis can be life saving. Elevated bilirubin levels are due to hepatocellular damage and disruption of intercellular junctions between hepatocytes, resulting in leaking of bilirubin out of bile caniliculi. Hemorrhagic complications are common and are associated with coagulation abnormalities. Severe pulmonary hemorrhage syndrome due to extensive alveolar hemorrhage has a fatality rate of >50 %. Readers are referred to earlier, excellent summaries related to this subject (Adler and de la Peña-Moctezuma 2010; Bharti et al. 2003; Hartskeerl et al. 2011; Ko et al. 2009; Levett 2001; McBride et al. 2005).

Indexed as

AnimalsBilirubinCost of IllnessHumansLeptospirosisRatsBilirubin

Identifiers

PMID25388133
PMCPMC4442676
OpenAlexW75505851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.